Overview

Safety, Tolerability, and PK of Escalating Doses of Flufirvitide-3 Dry Powder for Inhalation in Healthy Subjects

Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety, tolerability and pharmacokinetics (PK) of single,and repeat escalating doses of FF-3 dry powder administered via inhalation in healthy adult subjects
Phase:
Phase 1
Details
Lead Sponsor:
Autoimmune Technologies, LLC